Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in OncologyReport as inadecuate




Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology - Download this document for free, or read online. Document in PDF available to download.

Advances in Therapy

, Volume 33, Issue 11, pp 2059–2068

First Online: 07 October 2016Received: 05 August 2016DOI: 10.1007-s12325-016-0415-5

Cite this article as: Sacristán, J.A., Lizan, L., Comellas, M. et al. Adv Ther 2016 33: 2059. doi:10.1007-s12325-016-0415-5

Abstract

IntroductionThe purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of healthcare policy makers HCPM, oncologists, patients and the general population in Spain.

MethodsStructured interviews were conducted to assess: 1 the importance of the attributes on treatment choice when comparing a new cancer drug with a standard cancer treatment; 2 the importance of survival, quality of life QoL, costs and innovation in cancer; and 3 the most worrying side effects related to cancer drugs.

ResultsA total of 188 individuals participated in the study. For all participants, when choosing treatments, the best rated characteristics were greater efficacy, greater safety, treatment adaptation to patients’ individual requirements and the rapid reincorporation of patients to their daily activities. There were important differences among participants in their opinion about survival, QoL and cost. In general, oncologists, patients, and the general population gave greater value to gains in QoL than healthcare policy makers. Compared to other participants healthcare policy makers gave greater importance to the economic impact related to oncology treatments.

ConclusionsGains in QoL, survival, safety, cost and innovation are perceived differently by different groups of stakeholders. It is recommended to consider the perspective of different stakeholders in the assessment of a new cancer drugs to obtain more informed decisions when deciding on the most appropriate treatment to use.

FundingEli Lilly and Co, Madrid Spain.

KeywordsClinically meaningful outcomes Innovation Oncology Spain Value Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-14E6F0601466A5CC.

Download fulltext PDF



Author: José A. Sacristán - Luís Lizan - Marta Comellas - Pilar Garrido - Cristina Avendaño - Juan J. Cruz-Hernández - Javier

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents